Should I buy or sell Valneva stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VALN shares. View VALN analyst ratings or view top-rated stocks .

What is Valneva's stock price target for 2024?

3 brokerages have issued 12-month price targets for Valneva's stock. Their VALN share price targets range from $17.00 to $26.00. On average, they expect the company's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 179.6% from the stock's current price. View analysts price targets for VALN or view top-rated stocks among Wall Street analysts .

How have VALN shares performed in 2024?

Valneva's stock was trading at $10.37 at the start of the year. Since then, VALN shares have decreased by 25.3% and is now trading at $7.75. View the best growth stocks for 2024 here .

When is Valneva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VALN earnings forecast .

How were Valneva's earnings last quarter?

Valneva SE (NASDAQ:VALN) released its earnings results on Wednesday, March, 20th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of $0.20 by $0.70. The business had revenue of $45.12 million for the quarter, compared to analysts' expectations of $45.06 million. Valneva had a negative trailing twelve-month return on equity of 59.48% and a negative net margin of 65.99%.

What guidance has Valneva issued on next quarter's earnings?

Valneva updated its FY 2024 earnings guidance on Wednesday, March, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $172.2 million-$193.8 million, compared to the consensus revenue estimate of $245.0 million.

When did Valneva IPO?

Valneva (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VALN

Valneva (VALN) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free VALN Stock Alerts

$7.75

-0.25 (-3.13%)

(As of 04/17/2024 ET)

Compare

Today's Range: $7.50
▼
$7.79
50-Day Range: $6.63
▼
$8.89
52-Week Range: $6.58
▼
$17.05

Volume: 1,608 shs
Average Volume: 9,249 shs
Market Capitalization: $538.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.67

Get Valneva alerts:

Valneva MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 179.6% Upside
$21.67 Price Target
Short Interest: Bearish
0.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.90
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.11 to ($1.01) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.44 out of 5 stars

Medical Sector

704th out of 913 stocks

Biological Products, Except Diagnostic Industry

104th out of 134 stocks

3.5

Analyst's Opinion

Consensus Rating
Valneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Valneva has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.07% of the float of Valneva has been sold short.
Short Interest Ratio / Days to Cover
Valneva has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Valneva has recently increased by 12.03%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Valneva does not currently pay a dividend.
Dividend Growth
Valneva does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VALN.

3.3

News and Social Media Coverage

News Sentiment
Valneva has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Valneva this week, compared to 3 articles on an average week.
Search Interest
3 people have searched for VALN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
12 people have added Valneva to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Valneva insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.39% of the stock of Valneva is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Valneva are expected to decrease in the coming year, from $0.11 to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Valneva is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Valneva is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Valneva has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Valneva Stock (NASDAQ:VALN)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

VALN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VALN Stock News Headlines

April 12, 2024 | americanbankingnews.com

Valneva (NASDAQ:VALN) Shares Gap Up to $8.04

April 4, 2024 | finance.yahoo.com

Declaration of voting rights - Valneva SE, March 2024

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 27, 2024 | msn.com

Valneva commences Phase I trial of second-generation Zika vaccine

March 27, 2024 | markets.businessinsider.com

Buy Rating on Valneva Supported by Promising Vaccine Developments and Solid Revenue Projections

March 26, 2024 | globenewswire.com

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

March 25, 2024 | msn.com

2 new Lyme disease vaccines could mean end of debilitating illness

March 25, 2024 | globenewswire.com

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 22, 2024 | seekingalpha.com

Valneva SE (VALN) Q4 2023 Earnings Call Transcript

March 22, 2024 | markets.businessinsider.com

What Analysts Are Saying About Valneva Stock

March 21, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Valneva: Strong Core Growth and Strategic Financial Health

March 21, 2024 | finance.yahoo.com

Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript

March 21, 2024 | globenewswire.com

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

March 20, 2024 | msn.com

Valneva guides for nearly double product sales by 2026

March 20, 2024 | investorplace.com

VALN Stock Earnings: Valneva Misses Revenue for Q4 2023

March 20, 2024 | msn.com

Valneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance

March 20, 2024 | finance.yahoo.com

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

March 20, 2024 | reuters.com

French biotech company Valneva raises product sales guidance

March 20, 2024 | globenewswire.com

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

March 19, 2024 | msn.com

West Lothian sciences firm bags brace of awards

March 18, 2024 | globenewswire.com

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

March 12, 2024 | ft.com

The UK could be a vaccine superpower, but it needs a booster

March 11, 2024 | msn.com

Lexicon stock rallies 18% amid FDA update, $250M private placement

March 11, 2024 | finance.yahoo.com

Global Anthrax Vaccine Market Worth Over $22 Billion by 2034, Driven by Advanced Vaccine Developments and Rising Demand for Bioterrorism Defense

March 6, 2024 | finance.yahoo.com

VALNEVA Declaration of shares and voting rights - February 29, 2024

March 4, 2024 | globenewswire.com

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

See More Headlines

Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:VALN
CUSIP: N/A
CIK: 1836564
Web: valneva.com
Phone: 33-2-28-07-37-10
Fax: N/A
Employees: 676
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.67
High Stock Price Target: $26.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +179.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 70.45
P/E Growth: N/A
Net Income: $-109,780,000.00
Net Margins: -65.99%
Pretax Margin: -64.16%
Return on Equity: -59.48%
Return on Assets: -19.17%

Debt

Debt-to-Equity Ratio: 1.04
Current Ratio: 1.65
Quick Ratio: 1.37

Sales & Book Value

Annual Sales: $165.52 million
Price / Sales: 3.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.00 per share
Price / Book: 3.88

Miscellaneous

Outstanding Shares: 69,460,000
Free Float: 59,100,000
Market Cap: $538.32 million
Optionable: Not Optionable
Beta: 2.25

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Thomas Lingelbach (Age 61)
President, CEO & Director
Comp: $996.05k
Mr. Peter Buhler (Age 53)
Chief Financial Officer
Comp: $605.32k
Mr. Franck Grimaud MBA (Age 57)
Chief Business Officer
Comp: $434.73k
Dr. Juan-Carlos Jaramillo M.D. (Age 52)
Chief Medical Officer
Comp: $584.65k
Ms. Dipal Patel (Age 49)
Chief Commercial Officer
Comp: $559.74k
Mr. Joshua Drumm Ph.D.
Vice President of Investor Relations
Ms. Laetitia Bachelot-Fontaine
VP of Global Communications & European Investor Relations
Mr. Christian Taucher
Head of Global Medical Affairs
Ms. Susanne Eder-Lingelbach
Head of Clinical Operations
Katrin Dubischar
VP & Program Director of Chikungunya Vaccine

Key Competitors

View All Competitors

VALN Stock Analysis - Frequently Asked Questions

Should I buy or sell Valneva stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VALN shares.
View VALN analyst ratings or view top-rated stocks.
What is Valneva's stock price target for 2024?: 3 brokerages have issued 12-month price targets for Valneva's stock. Their VALN share price targets range from $17.00 to $26.00. On average, they expect the company's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 179.6% from the stock's current price.
View analysts price targets for VALN or view top-rated stocks among Wall Street analysts.
How have VALN shares performed in 2024?: Valneva's stock was trading at $10.37 at the start of the year. Since then, VALN shares have decreased by 25.3% and is now trading at $7.75.
View the best growth stocks for 2024 here.
When is Valneva's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VALN earnings forecast.

How were Valneva's earnings last quarter?: Valneva SE (NASDAQ:VALN) released its earnings results on Wednesday, March, 20th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of $0.20 by $0.70. The business had revenue of $45.12 million for the quarter, compared to analysts' expectations of $45.06 million. Valneva had a negative trailing twelve-month return on equity of 59.48% and a negative net margin of 65.99%.
What guidance has Valneva issued on next quarter's earnings?: Valneva updated its FY 2024 earnings guidance on Wednesday, March, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $172.2 million-$193.8 million, compared to the consensus revenue estimate of $245.0 million.
When did Valneva IPO?: Valneva (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.
How do I buy shares of Valneva?: Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VALN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Valneva (VALN) Stock Price, News & Analysis

Valneva MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Valneva Stock (NASDAQ:VALN)

VALN Stock Price History

VALN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

VALN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™